Physician profile
Puneet Dabas
NPI 1326488768
$22,833.95
in general payments reported to CMS, 2019-2025
66 companies · $6,513 in 2025
The $6,513 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,823 · 2020: $723 · 2021: $1,632 · 2022: $2,903 · 2023: $4,467 · 2024: $3,773 · 2025: $6,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Travel and Lodging: $236 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,402.71 |
| Travel and Lodging | $235.69 |
| Education | $113.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,016.40 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Biogen, INC. | $2,361.00 | 2019-2025 | Vumerity, Tysabri |
| Ucb, INC. | $2,274.94 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Sk Life Science, INC. | $1,170.72 | 2020-2025 | Xcopri |
| Amneal Pharmaceuticals LLC | $1,163.41 | 2019-2025 | Rytary, Crexont, Lyvispah |
| Novartis Pharmaceuticals Corporation | $881.51 | 2019-2025 | |
| Genentech USA, INC. | $868.70 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Teva Pharmaceuticals USA, INC. | $868.69 | 2020-2025 | Ajovy, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $782.46 | 2019-2025 | Ultomiris |
| Pfizer INC. | $731.98 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $703.31 | 2019-2025 | Nuplazid |
| Livanova USA, INC. | $652.45 | 2019-2023 | Vns Therapy |
| Lilly USA, LLC | $575.67 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Eisai INC. | $575.66 | 2023-2025 | |
| Emd Serono, INC. | $543.41 | 2019-2025 | Mavenclad |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneet Dabas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.